Cardiovascular disease and chronic kidney disease: Insights and an update

American Heart Journal

Volumn 148, Issue 2, 2004, Pages 230-242

  Best, Patricia J M ^a   Reddan, Donal N ^b   Berger, Peter B ^a   Szczech, Lynda A ^b   McCullough, Peter A ^c   Califf, Robert M ^b  

^a MAYO CLINIC   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPTIFIBATIDE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; RECOMBINANT ERYTHROPOIETIN; THROMBIN INHIBITOR;

ANEMIA; ATHEROGENESIS; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIALYSIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFLAMMATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ERYTHROPOIETIN, RECOMBINANT; GLOMERULAR FILTRATION RATE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASES; MYOCARDIAL REVASCULARIZATION; OXIDATIVE STRESS; RISK FACTORS; UNITED STATES;

EID: 4143068072     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.04.011     Document Type: Conference Paper

References (153)

1. US Renal Data System. USRDS 2003 annual data report. 2003;National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, M
2. Jones C.A., McQuillan G.M., Kusek J.W., et al. Serum creatinine levels in the US population third National Health and Nutrition Examination Survey. Am J Kidney Dis. 32:1998;992-999
3. Culleton B.F., Larson M.G., Evans J.C., et al. Prevalence and correlates of elevated serum creatinine levels the Framingham Heart Study. Arch Intern Med. 159:1999;1785-1790
4. Anonymous. Excerpts from the United States Renal Data System 1998 annual data report: V. patient mortality and survival. Am J Kidney Dis 1999;32(Suppl 1):S69-80
5. Locatelli F., Marcelli D., Conte F., et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol. 12:2001;2411-2417
6. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease what do we know? What do we need to learn? Where do we go from here? Am J Kid Dis. 32:1998;853-906
7. Brunner F.P., Selwood N.H. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney Int Suppl. 38:1992;S4-15
8. Parekh R.S., Carroll C.E., Wolfe R.A., et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 141:2002;191-197
9. Flack J.M., Neaton J.D., Daniels B., et al. Ethnicity and renal disease lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension study. Am J Kid Dis. 21:1993;31-40
10. Mann J.F., Gerstein H.C., Pogue J., et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril the HOPE randomized trial. Ann Intern Med. 134:2001;629-636
11. Al Suwaidi J., Reddan D.N., Williams K., et al. GUSTO-IIb, GUSTO-III, PURSUIT. Global Use of Strategies to Open Occluded Coronary Arteries. Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy. PARAGON-A Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 106:2002;974-980
12. McCullough P.A., Soman S.S., Shah S.S., et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol. 36:2000;679-684
13. Shlipak M.G., Heidenreich P.A., Noguchi H., et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 137:2002;555-562
14. Best P.J., Lennon R., Ting H.H., et al. Even mild renal insufficiency is associated with increased mortality after percutaneous coronary interventions. J Am Coll Cardiol. 39:2002;1113-1119
15. Liu J.Y., Birkmeyer N.J., Sanders J.H., et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation. 102:2000;2973-2977
16. Herzog C.A. Acute myocardial infarction in patients with end-stage renal disease. Kidney Int Suppl. 71:1999;S130-133
17. Herzog C.A., Ma J.Z., Collins A.J. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int. 56:1999;324-332
18. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41
19. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Int Med. 130:1999;461-470
20. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 35:2000;681-689
21. Anonymous. Executive summary-K/DOQI clinical practice guidelines. Am J Kidney Dis 2002;39(Suppl 1):S17-31
22. Rossing P, Hougaard P, Borch-Johnsen K, et al. Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. Br Med J 1996;313:779-84
23. Gall M.A., Borch-Johnsen K., Hougaard P., et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 44:1995;1303-1309
24. Yudkin J.S., Forrest R.D., Jackson C.A. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet. 2:1988;530-533
25. Festa A., D'Agostino R. Jr, Howard G., et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects the Insulin Resistance Atherosclerosis study. Kidney Int. 58:2000;1703-1710
26. Parfrey P.S., Foley R.N. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 10:1999;1606-1615
27. Parfrey P.S., Foley R.N., Rigatto C. Risk issues in renal transplantation cardiac aspects. Transplant Proc. 31:1999;291-293
28. Marso S.P., Ellis S.G., Gurm H.S., et al. Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. Am Heart J. 139:2000;939-944
29. Ohashi H., Oda H., Ohno M., et al. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl. 71:1999;S242-244
30. Kronenberg F., Neyer U., Lhotta K., et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients a prospective follow-up. J Am Soc Nephrol. 10:1999;1027-1036
31. US Renal Data System. USRDS 2001 annual data report atlas of end-stage renal disease in the United States. 2001;National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md
32. Szczech L.A., Best P.J., Crowley E., et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation. 105:2002;2253-2258
33. Tvedegaard E., Falk E., Nielsen M. Uremic arterial disease in rabbits with special reference to the coronary arteries. Acta Pathol Microbiol Immunol Scand. 93:1985;81-88
34. Tvedegaard E., Kamstrup O. The effect of chronic renal failure in rabbits on plasma lipids and the concentration of cholesterol, calcium and phosphate in the aortic wall. Proc Eur Dial Transplant Assoc. 17:1980;240-246
35. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng J Med. 342:2000;1478-1483
36. Weiss T., Windthorst C., Weiss C., et al. Acute effects of haemodialysis on cutaneous microcirculation in patients with peripheral arterial occlusive disease. Nephrol Dial Transplant. 13:1998;2317-2321
37. Tetta C., Gallieni M., Panichi V., et al. Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients a need for a neutral calcium balance during hemodialysis? Int J Artif Organs. 25:2002;18-26
38. Kiamk E., Solski J., Janicka L., et al. Lipid and lipoprotein ratios as risk factors of atherosclerosis in patients with chronic renal insufficiency. Int Urol Nephrol. 31:1999;263-267
39. Shoji T., Nishizawa Y., Kawagishi T., et al. Atherogenic lipoprotein changes in the absence if hyperlipidemia in patients with chronic renal failure treated by dialysis. Atherosclerosis. 131:1997;229-236
40. Haffner S.M., Gruber K.K., Aldrete G. Jr, et al. Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol. 3:1992;1156-1162
41. Heimann P., Josephson M.A., Fellner S.K., et al. Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients. Am J Nephrol. 11:1991;470-474
42. Kronenberg F., Kathrein H., König P., et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb. 14:1994;1405-1411
43. Koch M., Kutkuhn B., Trenkwalder E., et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 8:1997;1889-1898
44. Arnadottir M., Thysell H., Dallongeville J., et al. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 48:1995;779-784
45. Lee P., O'Neal D., Murphy B., et al. The role of abdominal adiposity and insulin resistance in dyslipidemia of chronic renal failure. Am J Kid Dis. 29:1997;54-65
46. Tamashiro M., Iseki K., Sunagawa O., et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis. 38:2001;64-69
47. Fleischmann E.H., Bower J.D., Salahudeen A.K. Risk factor paradox in hemodialysis better nutrition as a partial explanation. ASAIO J. 47:2001;74-81
48. Chertow G.M., Johansen K.L., Lew N., et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int. 57:2000;1176-1181
49. Fleischmann E., Teal N., Dudley J., et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 55:1999;1560-1567
50. Stenvinkel P., Heimbürger O., Tuck C., et al. Apo(a) isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 53:1998;1336-1342
51. Schettler V., Wieland E., Methe H., et al. Oxidative stress during dialysis effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Nephrol Dial Transplant. 13:1998;2588-2593
52. Handelman G.J., Walter M.F., Adhikarla R., et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 59:2001;1960-1966
53. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 161:1998;2524-2532
54. Al-Saady N.M., Leatham E.W., Gupta S., et al. Monocyte expression of tissue factor and adhesion molecules the link with accelerated coronary artery disease in patients with chronic renal failure. Heart. 81:1999;134-140
55. Maor I., Kaplan M., Hayek T., et al. Oxidized monocyte-derived macrophages in aortic atherosclerotic lesion from apolipoprotein E-deficient mice and from human carotid artery contain lipid peroxides and oxysterols. Biochem Biophys Res Commin. 269:2000;775-780
56. Spittle M.A., Hoenich N.A., Handelman G.J., et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kid Dis. 38:2001;1408-1413
57. Maccarrone M., Meloni C., Manca-di-Villahermosa S., et al. Vitamin E suppresses 5-lipoxygenase-mediated oxidative stress in peripheral blood mononuclear cells of hemodialysis patients regardless of administration route. Am J Kid Dis. 37:2001;964-969
58. Wever R., Boer P., Hijmering M., et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 19:1999;1168-1172
59. Miyazaki H., Matsuoka H., Itabe H., et al. Hemodialysis impairs endothelial function via oxidative stress effects of vitamin E-coated dialyzer. Circulation. 101:2000;1002-1006
60. Moustapha A., Naso A., Nahlawi M., et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 97:1998;138-141
61. van Guldener C., Kulik W., Berger R., et al. Homocysteine and methionine metabolism in ESRD a stable isotope study. Kidney Int. 56:1999;1064-1071
62. Cordoba-Porras A., Sanchez-Quesada J.L., Gonzalez-Sastre F., et al. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med. 74:1996;771-776
63. Kanani P.M., Sinkey C.A., Browning R.L., et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 100:1999;1161-1168
64. Hultberg B., Andersson A., Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology. 123:1997;33-40
65. Tawakol A., Omland T., Gerhard M., et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 95:1997;1119-1121
66. Herrmann W., Quast S., Ellgass A., et al. An increased serum level of free Apo(a) in renal patients is more striking than that of Lp(a) and is influenced by homocysteine. Nephron. 85:2000;41-49
67. Dardik R., Varon D., Tamarin I., et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions distinct mechanisms of thrombogenic modulation. Thromb Haemo. 83:2000;338-344
68. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke a meta-analysis. JAMA. 288:2002;2015-2022
69. Toss H., Lindahl B., Siegbahn A., et al. FRISC Study Group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease. Circulation. 96:1997;4141-4142
70. Benderly M., Graff E., Reicher-Reiss H., et al. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol. 16:1996;351-356
71. Romanic A.M., Arleth A.J., Willette R.N., et al. Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions. Circ Res. 83:1998;264-269
72. Remuzzi G., Mingardi G., Mecca G., et al. Does aspirin precipitate major gastrointestinal bleeding in patients on haemodialysis. Lancet. 2:1977;359-360
73. Remuzzi G. Bleeding in renal failure. Lancet. 1:1988;1205-1208
74. Livio M., Benigni A., Vigano G., et al. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet. 8478:1986;414-416
75. McCullough P.A., Sandberg K.R., Borzak S., et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 144:2002;226-232
76. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502
77. Steinhubl S.R., Berger P.B., Mann J.T. III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial. JAMA. 288:2002;2411-2420
78. Best PJM, Berger PB, Brennan D, et al. The efficacy of long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease (abstract). Circulation 2003;108(Supp IV):333
79. Zoccali C., Mallamaci F., Parlongo S., et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 105:2002;1354-1359
80. Cice G., Tagliamonte E., Ferrara L., et al. Complex ventricular arrhythmias and carvedilol efficacy in hemodialyzed uremic patients. Cardiologia. 43:1998;597-604
81. Tonelli M., Bohm C., Pandeya S., et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kid Dis. 36:(6 Suppl 3):2001;S24-30
82. Cice G., Di Benedetto A., D'Andrea A., et al. Sustained-release diltiazem reduces myocardial ischemic episodes in end-stage renal disease a double-blind, randomized, crossover, placebo-controlled trial. J Am Soc Nephrol. 14:2003;1006-1011
83. Kestenbaum B., Gillen D.L., Sherrard D.J., et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 61:2002;2157-2164
84. Bakris G.L., Weir M.R., DeQuattro V., McMahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 54:1998;1283-1289
85. Tisler A., Akocsi K., Harshegyi I., et al. Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension. Kidney Blood Press Res. 25:2002;97-102
86. Kurata N., Nakamura S., Mizumura J., et al. Enhancement of nitroglycerin induced blood vessel relaxation in chronic renal failure model rats. Res Commun Mol Pathol Pharmacol. 106:1999;23-36
87. Berl T., Hunsicker L.G., Lewis J.B., et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 138:2003;542-549
88. Efrati S., Zaidenstein R., Dishy V., et al. ACE inhibitors and survival of hemodialysis patients. Am J Kid Dis. 40:2002;1023-1029
89. Swedberg K., Eneroth P., Kjekshus J., et al. CONSENSUS Trial Study Group. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol. 66:1990;40-44D
90. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462
91. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 139:2003;244-252
92. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860
93. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis a randomized controlled trial. JAMA. 285:2001;2719-2728
94. Hillege H.L., van Gilst W.H., van Veldhuisen D.J., et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition the CATS randomized trial. Eur Heart J. 24:2003;412-420
95. Levin A., Duncan L., Djurdjev O., et al. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency diet modification with or without fenofibrate. Clin Nephrol. 53:2000;140-146
96. Akcicek F., Ok E., Duman S., et al. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients a prospective cross-over study. Adv Peritoneal Dialys. 12:1996;261-265
97. Irish A.B., Thompson C.H. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Nephrol Dial Transplant. 11:1996;2223-2228
98. Wanner C., Horl W.H., Luley C.H., et al. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int. 39:1991;754-760
99. Nishikawa O., Mune M., Miyano M., et al. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int. 71:1999;S219-221
100. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering new concepts for cardiovascular disease. Cardiovasc Res. 49:2001;281-287
101. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci. 23:2002;482-486
102. Pruefer D., Makowski J., Schnell M., et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation. 106:2002;2104-2110
103. Weber C., Erl W., Weber K.S.C., et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 30:1997;1212-1217
104. Diomede L., Albani D., Sottocorno M., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 21:2001;1327-1332
105. Ferro D., Parrotto S., Basili S., et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol. 36:2000;427-431
106. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA activity stability by Rho GTPase. J Biol Chem. 273:1998;24266-24271
107. Wilson S.H., Simari R.D., Best P.J., et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 21:2001;122-128
108. Tonelli M., Moye L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 138:2003;98-104
109. Stewart-Phillips J.L., Gagnon R.F., Lough J. Atherosclerosis in uremic mice. ASAIO Trans. 35:1989;631-634
110. Hirsh J., Anand S.S., Halperin J.L., et al. Guide to anticoagulant therapy heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 103:2001;2994-3018
111. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119:2001;64-94S
112. Bjornsson T.D., Wolfram K.M., Kitchell B.B. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 31:1982;104-113
113. de Swart C.A., Nijmeyer B., Roelofs J.M., et al. Kinetics of intravenously administered heparin in normal humans. Blood. 60:1982;1251-1258
114. Glimelius B., Busch C., Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res. 12:1978;773-782
115. Mahadoo J., Heibert L., Jaques L.B. Vascular sequestration of heparin. Thromb Res. 12:1978;79-90
116. Friedman Y., Arsenis C. Studies on the heparin sulphamidase activity from rat spleen intracellular distribution and characterization of the enzyme. Biochem J. 139:1974;699-708
117. House A.K., Potter J.M., Smith P.A., et al. Heparinization in aortic surgery. J Cardiovasc Surg. 29:1988;707-711
118. Oster J.R., Singer I., Fishman L.M. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 98:1995;575-586
119. Edes T.E. Heparin-induced hyperkalemia. Postgrad Med. 87:1990;104-106
120. Gerlach A.T., Pickworth K.K., Seth S.K., et al. Enoxaparin and bleeding complications a review in patients with and without renal insufficiency. Pharmacotherapy. 20:2000;771-775
121. Frydman A. Low-molecular-weight heparins an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 26:1996;24-38
122. Cadroy Y., Pourrat J., Baladre M.F., et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res. 63:1991;385-390
123. Cornelli U., Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Hemost. 25:1999;57-61
124. Becker R.C., Spencer F.A., Gibson M., et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 143:2002;753-759
125. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 12:(Suppl F):2000;33F-36F
126. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 12:(Suppl F):2000;33F-36F
127. Fernandez J.S., Sadaniantz A. Medical and revascularization management in acute coronary syndrome in renal patients. Semin Nephrol. 21:2001;25-35
128. Lincoff A.M., Califf R.M., Moliterno D.J., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 341:1999;319-327
129. Lincoff A.M. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol. 82:1998;36-42P
130. Best P.J.M., Lennon R., Gersh B.J., et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 146:2003;345-350
131. Freeman R.V., Mehta R.H., Al Badr W., et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 41:2003;718-724
132. Reddan D.N., O'Shea J.C., Sarembock I.J., et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial). Am J Cardiol. 91:2003;17-21
133. Rinehart A.L., Herzog C.A., Collins A.J., et al. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis. 25:1995;281-290
134. Schoebel F.C., Gradaus F., Ivens K., et al. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease a case-control study using quantitative coronary angiography. Heart. 78:1997;337-342
135. Azar R.R., Prpic R., Ho K.K., Baim D.S., et al. Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am J Cardiol. 86:2000;485-489
136. Szczech L.A., Reddan D.N., Owen W.F., et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int. 60:2001;292-299
137. Reddan D.N., Szczech L.A., Tuttle R.H., et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol. 14:2003;2373-2380
138. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 335:1996;217-225
139. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetes status. J Am Coll Cardiol. 35:2000;1122-1129
140. Obrador G.T., Roberts T., St Peter W.L., et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int. 60:2001;1875-1884
141. Kazmi W.H., Kausz A.T., Khan S., et al. Anemia an early complication of chronic renal insufficiency. Am J Kid Dis. 38:2001;803-812
142. Yang C.-S., Chen S.-W., Chiang C.-H., et al. Effects of increasing dialysis dose on serum albumin and mortality in hemodialysis patients. Am J Kidney Dis. 27:1996;380-386
143. Madore F., Lowrie E.G., Brugnara C., et al. Anemia in hemodialysis patients variables affecting this outcome predictor. J Am Soc Nephrol. 8:1997;1921-1929
144. Mocks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study. Nephron. 86:2000;455-462
145. Foley R.N., Parfrey P.S., Harnett J.D., et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis. 28:1996;53-61
146. Macdougall I.C., Lewis N.P., Saunders M.J., et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet. 335:1990;489-493
147. Hayashi T., Suzuki A., Shoji T., et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 35:2000;250-256
148. Sikole A., Polenakovic M., Spiroska V., et al. Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif Organs. 26:2002;98-102
149. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 58:2000;1325-1335
150. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 339:1998;584-590
151. European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 5):5-13
152. Dove A. FDA in a quandary over Pediatric Rule. Nat Med. 8:2002;541-542
153. Ryden L., Armstrong P.W., Cleland J.G., et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus results from the ATLAS trial. Eur Heart J. 21:2000;1967-1978